Table 5.
The Cohen’s kappa coefficient concordance analysis of expression status in breast PTs and synchronous ALN metastases.
| Primary tumor | ALN metastases | ||
|---|---|---|---|
| 0 | 1 | Kappa | |
| ER (n = 49) | 0.46** | ||
| 0 | 6 | 6 | |
| 1 | 3 | 34 | |
| PR (n = 46) | 0.54*** | ||
| 0 | 19 | 7 | |
| 1 | 3 | 15 | |
| Ki-67 (n = 43) | 0.51*** | ||
| 0 | 21 | 5 | |
| 1 | 5 | 12 | |
| HER2 (n = 31†) | 1* | ||
| 0 | 27 | 0 | |
| 1 | 0 | 4 | |
| E-cadherin (n = 23) | 0 | ||
| 0 | 0 | 0 | |
| 1 | 12 | 11 | |
| Cyclin D1 (n = 44) | 0.28 | ||
| 0 | 3 | 6 | |
| 1 | 3 | 32 | |
| Bcl-2 (n = 42) | 0.38* | ||
| 0 | 7 | 7 | |
| 1 | 4 | 25 | |
| GCDFP-15 (n = 50) | 0.28* | ||
| 0 | 11 | 8 | |
| 1 | 9 | 22 | |
| SNAIL+SLUG (n = 21) | 0.64* | ||
| 0 | 1 | 1 | |
| 1 | 0 | 19 | |
| PD-L1 (n = 22) | -0.12* | ||
| 0 | 17 | 2 | |
| 1 | 3 | 0 | |
| PRL-3 (n = 21) | 0.08 | ||
| 0 | 2 | 3 | |
| 1 | 5 | 11 | |
†The analysis was performed excluding cases of 2+ intensity score.
*p-value < 0.05.
**p-value < 0.001.
***p-value < 0.0001.
ALN, axillary lymph node; ER, estrogen receptor; PR, progesterone receptor; PT, primary tumor.